Share This Page
Drug Price Trends for NDC 00904-7282
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7282
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METHYLERGONOVINE 0.2 MG TABLET | 00904-7282-10 | 7.89254 | EACH | 2024-12-25 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7282
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
00904-7282 Market Analysis and Financial Projection
Market Analysis and Price Projections for the Drug NDC: 00904-7282
Understanding the National Drug Code (NDC)
The National Drug Code (NDC) is a unique, three-segment number that identifies drug products in the United States. For the NDC 00904-7282, each segment provides specific information: the labeler code, product code, and package code. The labeler code (00904) identifies the firm that manufactures, repacks, or relabels the drug. The product code and package code specify the drug's strength, dosage form, formulation, and packaging details[1].
Drug Identification and Listing
To analyze the market and price projections for the drug with NDC 00904-7282, it is crucial to identify the drug product. This involves checking the FDA's NDC Directory, which lists prescription drugs, over-the-counter (OTC) drugs, and insulin products that are commercially distributed. The directory provides details such as the drug's name, strength, dosage form, and the firm responsible for its distribution[1][5].
Market Context and Pricing Trends
Global and U.S. Pricing Comparisons
Prescription drug prices in the U.S. are significantly higher compared to other countries. According to the ASPE, prices in the U.S. were 5.5 times those in the OECD (excluding the U.S.) and 7.7 times prices in the rest of the world (excluding the U.S.) by 2022. This disparity is partly due to the drug mix in the U.S., which tends to include more expensive compounds[4].
Recent Price Increases
Many prescription drugs, including those selected for Medicare Part D negotiations, have seen substantial price increases. Between 2018 and 2023, nine out of ten drugs selected for negotiation had list price increases ranging from 20% to 55%. This trend indicates that drug prices are rising, contributing to affordability challenges for patients and healthcare payers[2].
Medicare Part D Negotiations
Impact on Drug Prices
Beginning in January 2026, Medicare Part D will implement negotiated prices for selected drugs, which could significantly impact the pricing landscape. For the first cycle of negotiation, discounts ranged from 38% to 79% compared to list prices. This suggests that future price negotiations could lead to lower costs for Medicare enrollees and potentially influence broader market pricing[2].
Predictions and Trends in the Pharmaceutical Industry
Role of AI and Data
In 2025, the pharmaceutical industry is expected to see increased adoption of artificial intelligence (AI) in clinical development and data analysis. This includes using external data to train internal models and leveraging large language models (LLMs) for decision-making. Such advancements could improve efficiency and accuracy in drug development and pricing strategies[3].
Specific Analysis for NDC 00904-7282
Identifying the Drug
To provide a detailed analysis, it is necessary to identify the specific drug associated with the NDC 00904-7282. This involves searching the FDA's NDC Directory or other pharmaceutical databases.
Historical Pricing Data
Reviewing historical pricing data for the identified drug will help in understanding past trends. This can include list price changes, discounts, and any regulatory or market factors that have influenced its pricing.
Market Demand and Competition
Analyzing market demand and competition for the drug is crucial. Factors such as the number of prescriptions, patient population, and competitor drugs can influence pricing strategies.
Regulatory and Policy Changes
Changes in regulatory policies, such as those related to Medicare Part D negotiations, can significantly impact drug prices. Monitoring these changes is essential for accurate price projections.
Price Projections
Short-Term Projections
Given the current trends of rising drug prices and the upcoming Medicare Part D negotiations, short-term price projections for the drug with NDC 00904-7282 may include:
- Potential discounts if the drug is selected for Medicare Part D negotiations.
- Continued price increases if the drug is not subject to negotiation.
Long-Term Projections
Long-term projections will depend on various factors, including:
- The adoption of AI and data analytics in the pharmaceutical industry, which could lead to more efficient and cost-effective drug development.
- Global pricing trends and regulatory changes that could influence U.S. drug prices.
- Market demand and competition, which can drive pricing strategies.
Key Takeaways
- The NDC 00904-7282 identifies a specific drug product, and understanding its components is crucial for market analysis.
- U.S. drug prices are significantly higher than in other countries, and recent trends show substantial price increases.
- Medicare Part D negotiations are expected to lower prices for selected drugs, potentially influencing broader market pricing.
- The pharmaceutical industry's increasing use of AI and data analytics could impact future pricing strategies.
FAQs
What is the National Drug Code (NDC), and how is it structured?
The National Drug Code (NDC) is a unique 10-digit number that identifies drug products. It is structured into three segments: the labeler code, product code, and package code, which together identify the labeler, specific drug product, and packaging details[1].
Why are drug prices in the U.S. higher than in other countries?
Drug prices in the U.S. are higher due to several factors, including the drug mix, which tends to include more expensive compounds, and the lack of price controls compared to other countries[4].
How will Medicare Part D negotiations affect drug prices?
Medicare Part D negotiations are expected to result in significant discounts for selected drugs, ranging from 38% to 79% compared to list prices. This could lower costs for Medicare enrollees and influence broader market pricing[2].
What role will AI and data analytics play in the pharmaceutical industry in 2025?
In 2025, AI and data analytics are expected to play a more significant role in clinical development, decision-making, and training internal data science models. This could improve efficiency and accuracy in drug development and pricing strategies[3].
Where can I find historical pricing data for a specific drug?
Historical pricing data for a specific drug can be found through the FDA's NDC Directory, pharmaceutical databases, and market research reports.
Sources
- FDA: National Drug Code Database Background Information - FDA
- ASPE: Medicare Drug Price Negotiation Program - ASPE - HHS.gov
- Intelligencia.ai: 2025 Pharma Predictions: AI, Health Tech, and Data Trends to Watch
- ASPE: ISSUE BRIEF - ASPE
- YouTube: NDC Directory (March 2015) - YouTube
More… ↓
